5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene

• ChemBase编号: 73043
• 分子式: C17H20N4S
• 平均质量: 312.4325
• 单一同位素质量: 312.14086766
• SMILES: N1c2c(C(=Nc3c1cccc3)N1CCN(CC1)C)cc(s2)C
• Canonical SMILES: CN1CCN(CC1)C1=Nc2ccccc2Nc2c1cc(s2)C
• InChI: InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
• InChIKey: KVWDHTXUZHCGIO-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^3,^7]tetradeca-1(14),3(7),5,8,10,12-hexaene; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^3,^7]tetradeca-1(10),3(7),5,8,11,13-hexaene
• IUPAC传统名: 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene; zyprexa; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^3,^7]tetradeca-1(10),3(7),5,8,11,13-hexaene; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^3,^7]tetradeca-1(14),3(7),5,8,10,12-hexaene
• 别名: Zyprexa; Zalasta; Zolafren; Olzapin; Oferta; Olanzapine; 2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine; LY-170053; Olanzapine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; Integrol; LY 170053; Lanzac; Oleanz; Oliza; Oltal; Zyprexa Zydis; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene; 2-Methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine

登记号

• CAS号: 132539-06-1
• MDL号: MFCD00866702
• Beilstein号: 7655141
• PubChem SID: 162037963
• PubChem CID: 4585

理论计算性质

• Acid pKa: 14.174461
• 质子受体: 4
• 质子供体: 1
• LogD (pH = 5.5): 1.2482201
• LogD (pH = 7.4): 2.9497752
• Log P: 3.388495
• 摩尔折射率: 93.8737 cm^3
• 极化性: 34.417046 Å^3
• 极化表面积: 30.87 Å^2
• 可自由旋转的化学键: 0
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: Acetronitrile; DMSO; DMSO: >15 mg/mL; Methanol
• 外观: yellow powder; Yellow Solid
• 熔点: 195°C
• 疏水性(logP): 3.009

安全信息

• 保存条件: -20°C; -20°C Freezer
• 欧盟危险性物质标志: 刺激性(Irritant) (Xi)
• 德国WGK号: 3
• 危险公开号: 36/38
• 安全公开号: 26
• GHS危险品标识: GHS07
• GHS警示词: Warning
• GHS危险声明: H315-H319-H413
• GHS警示性声明: P305 + P351 + P338
• 保存温度: 2-8°C

药理学性质

• 生物活性机理: 5HT(2) and dopamine D2 receptor antagonist

产品相关信息

• 纯度: ≥98% (HPLC); 95%; 95+%
• 成盐信息: Free Base
• 应用领域: Antipsychotic agent; Used in the treatment of schizophrenia and bipolar disorder
• Empirical Formula (Hill Notation): C17H20N4S

详细说明

Selleck Chemicals - S2493

Research Area: Cardiovascular Disease
Biological Activity:
Olanzapine(Zyprexa) is a high affinity for 5-HT2 serotonin and D2 dopamine receptor antagonist. It has a higher affinity for 5-HT2 serotonin receptors than D2 dopamine receptors. Like most atypical antipsychotics, compared to the older typical ones, olanzapine has a lower affinity for histamine, cholinergic muscarinic and alpha adrenergic receptors. Olanzapine also exhibits weak affinity for GABAA, BZD receptor site which may contribute slightly to its sedating properties. Antagonizing H1 histamine receptors causes sedation and may cause weight gain, although antagonistic actions at 5-HT2C receptors have also been implicated in weight gain. [1]

Sigma Aldrich - O1141

Biochem/physiol Actions
Olanzapine is a 5-HT2 serotonin and D1/D2 dopamine receptor antagonist.

Toronto Research Chemicals - O253750

A serotonin (5-HT2) and dopamine (D1/D2) receptor antagonist with anticholinergic activity. Antipsychotic.

参考文献

• http://en.wikipedia.org/wiki/Olanzapine
• Moore, N.A., et al.: Curr. Opin Invest. Drugs, 2, 281 (1993)
• Baldwin, D.S. and Montgomery, S.A.: Int. Clin. Psychopharmacol., 10, 239 (1993)
• Tohen, M., et al.: Am. J. Psychiatry, 156, 702 (1999)
• Eur. Pat., 1991, Lilly, 454 436; CA, 116, 83703u, (synth, pharmacol)
• Moore, N.A. et al., J. Pharmacol. Exp. Ther., 1992, 262, 545, (pharmacol)
• Fulle, R.W. et al., Res. Commun. Chem. Pathol. Pharmacol., 1992, 77, 87, (pharmacol)
• Fulton, B. et al., Drugs, 1997, 53, 281-298, (rev)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 683
• Bhana, N. et al., Drugs, 2001, 61, 111-161, (rev)